People with type 2 diabetes treated with a DPP-4 inhibitor are not at higher risk of pancreatic disease than those treated with other anti-hyperglycaemic drugs, a review by Queensland researchers has found. While some previous studies have suggested a small increased risk of acute pancreatitis in patients using DPP-4 inhibitors, a new review by researchers ...
No increase in pancreatitis risk with DPP-4 inhibitors, Australian review finds
By Michael Woodhead
18 Oct 2018